# Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

> **NCT00893789** · PHASE3 · TERMINATED · sponsor: **Cephalon, Inc.** · enrollment: 117 (actual)

## Conditions studied

- Traumatic Brain Injury

## Interventions

- **DRUG:** Armodafinil
- **DRUG:** Armodafinil
- **DRUG:** Armodafinil
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00893789
- **Lead sponsor:** Cephalon, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04-30
- **Primary completion:** 2011-01-31
- **Final completion:** 2011-01-31
- **Target enrollment:** 117 (ACTUAL)
- **Why stopped:** Study has been stopped by sponsor decision.
- **Last updated:** 2021-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00893789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00893789, "Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00893789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*